Aurinia Pharmaceuticals (AUPH) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
5 figures withheld by our checks. Each blank figure names its reason.
129.4mn → 138.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
steady at 0.1% of revenue (−10.3% YoY).
$98.2M returned vs $135.4M of FCF in FY25. Buybacks covered by cash flow.
101¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Net margin 101.5% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 321,738.0 | 283,055.0 | 235,133.0 | 175,513.0 | 134,030.0 | 45,605.0 | ▲20.4% | +57.8% |
Cost of revenue | 30,165.0 | 32,665.0 | 28,248.0 | 14,148.0 | 5,664.0 | 1,091.0 | ▲15.6% | +133.9% |
Gross profit | 291,573.0 | 250,390.0 | 206,885.0 | 161,365.0 | —A | —A | ▲21.0% | +24.6% |
Research & development | 48,028.0 | 32,505.0 | 20,785.0 | 49,641.0 | 44,988.0 | 51,139.0 | ▲56.4% | −10.7% |
Selling, general & admin | 99,476.0 | 101,794.0 | 172,028.0 | 195,036.0 | 196,371.0 | 173,536.0 | ▼40.8% | −12.5% |
Total operating expenses | 135,208.0 | 145,476.0 | 211,572.0 | 253,056.0 | 239,836.0 | 225,249.0 | ▼31.2% | −10.4% |
Operating incomefeeds ROC rank | 156,365.0 | 104,914.0 | −4,687.0 | −91,691.0 | −111,470.0 | −180,735.0 | — | — |
Other income, net | 10,751.0 | 9,243.0 | 12,135.0 | 14,222.0 | 5,118.0 | 529.0 | — | — |
Pretax income | 167,116.0 | 114,157.0 | 7,448.0 | −77,469.0 | −106,352.0 | −180,206.0 | ▲1432.7% | — |
Income tax | −147,150.0 | −173,045.0 | 1,696.0 | 551.0 | 1,828.0 | 760.0 | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 314,266.0 | 287,202.0 | 5,752.0 | −78,020.0 | −108,180.0 | −180,966.0 | ▲4893.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 2.28 | 2.07 | 0.04 | −0.54 | −0.76 | −1.40 | ▲5075.0% | — |
Diluted shares (mn) | 135.17 | 138.70 | 146.19 | 143.24 | 141.91 | 129.37 | ▼5.1% | +1.8% |
| Margins | ||||||||
Gross margin86th pct in Healthcare | 90.6% | 88.5% | 88.0% | 91.9% | —A | —A | ▲0.5pp | −3.5pp |
Operating margin | 48.6% | 37.1% | −2.0% | −52.2% | −83.2% | −396.3% | ▲39.1pp | +433.4pp |
Net margin | 97.7% | 101.5% | 2.4% | −44.5% | −80.7% | −396.8% | ▲99.0pp | +498.3pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Aurinia Pharmaceuticals' revenue last fiscal year?
Aurinia Pharmaceuticals reported revenue of $283.1M in fiscal 2025, up 20.4% from fiscal 2024.
What was Aurinia Pharmaceuticals' net income?
Aurinia Pharmaceuticals reported net income of $287.2M in fiscal 2025, a net margin of 101.5%.

